OBI-3424 is under clinical development by OBI Pharma and currently in Phase II for Pancreatic Cancer. According to GlobalData, Phase II drugs for Pancreatic Cancer have a 25% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how OBI-3424’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
OBI-3424 overview
TH-3424 (OBI-3424) is under development for the treatment of AKR1C3 over expressed tumors including hepatocellular (liver) cancer (HCC), metastatic castrate resistant prostate cancer (CRPC), solid tumors like pancreatic cancer, and T-cell acute lymphoblastic leukemia (T-ALL), peripheral T-cell lymphoma, prostate cancer, bladder cancer, renal cell carcinoma, gastric cancer, esophageal cancer, colorectal cancer, non-small cell lung cancer, endometrial cancer, extranodal NK/T cell lymphoma, acute myeloid leukemia, high-risk myelodysplastic syndrome, salivary gland cancer, breast cancer and cholangiocarcinoma. It is a small molecule prodrug that targets AKR1C3. It is administered through intravenous route.
OBI Pharma overview
OBI Pharma is a clinical-stage oncology company that develops therapies for the treatment of cancer and infectious diseases. The company’s pipeline products include adagloxad simolenin, an active immunotherapy that is intended for the treatment of metastatic breast cancer. Its other pipelines include OBI-833, OBI-3424, OBI-992, OBI-902, OBI-904 and BsADC fo the indications (NSCLC) non-small cell lung cancer, liver (HCC) hepatocellular carcinoma and T-ALL and solid tumor. The company work in collaboration with research institutes including cancer centers to enhance its pipeline products. The company operates in the US, Taiwan, Hong Kong, Australia and China. OBI Pharma is headquartered in Taipei, Taiwan.
For a complete picture of OBI-3424’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
